



Introduction

The importance of triage

- Accurate triage is an effective tool to release resources to patients who need it.
- The process of triage may differ between departments according to workflows and skill sets. • We advocate that appropriate clinical time is devoted to triage. This is of even greater importance under high demand/reduced capacity settings: national experience suggests that clinical focus on triage releases both time and capacity for scanning.

Determining follow up interval*

Where follow up is recommended over a period of time (e.g. 1-2 years), the decision as to the time frame for surveillance should be made depending on the severity present. For example low moderate disease should have less frequent follow up than moderate disease which is approaching cut off values for severe categorisation.

AORTIC STENOSIS Severe AS: GP advice: cardiology referral (see red-flags for urgent referral criteria) Echo surveillance interval if asymptomatic: 6 months Moderate AS: **GP advice:** routine cardiology referral indicated Echo surveillance interval if asymptomatic: 12 - 24 months* Mild AS: **GP** advice: cardiology referral indicated if bicuspid AV/post-inflammatory process/ previous radiotherapy Echo surveillance interval: if clinically indicated, echo in 3 years **BICUSPID AORTIC VALVE: GP advice:** Cardiology referral recommended **Echo surveillance interval bicuspid aortic valve:** If no AS and no more than mild AR: 3 years • If valve thickening and mild AS: 2 years If aortopathy individualised approach: 12 months surveillance default **RED FLAGS REQUIRING URGENT CARDIOLOGY (WITHIN 2 WEEKS) REVIEW:** Symptoms • Breathlessness; chest pain or heart failure signs require urgent cardiology review • Presyncope; syncope: consider in-patient admission Consider advanced imaging if symptoms associated with moderate valve disease Impaired LV • New LV dysfunction (LVEF <55% without other cause) **Reducing LV ejection fraction** • Reducing LVEF on sequential scans (where EF falling < 60%) **Aortic dimensions** • Aortic root surgery can be considered in those undergoing valve replacement when aortic root >45mm Bicuspid aortic valve with Ao root >50 mm Tricuspid aortic valve with Ao root >55 mm *Cardiology referral is **not** indicated when valve intervention is highly unlikely to alter prognosis or quality of life (e.g. terminal illness, significant frailty) **AORTIC REGURGITATION** Severe AR: **GP** advice: cardiology referral (see red-flags for urgent referral criteria) Echo surveillance interval if asymptomatic: 6 - 12 months' Moderate AR: **GP advice:** routine cardiology referral indicated Echo surveillance interval if asymptomatic: 12 - 24 months* Mild AR: **GP** advice: routine cardiology referral indicated if a rotic root \geq 40 mm or valve anatomically abnormal Echo surveillance interval: Ao root <40 mm and anatomically normal valve - no routine follow-up Ao root \geq 40 mm or anatomically abnormal valve - echo in 3 - 5 years* for AR surveillance. Individualised approach for monitoring of aortic root **BICUSPID AORTIC VALVE:** See AS section **RED FLAGS REQUIRING URGENT CARDIOLOGY REVIEW:** Symptoms Consider advanced imaging if symptoms associated with moderate valve disease Left ventricular size and systolic function LV dilatation LV impairment (LVEF <55% without other cause) An increase in LV size or decrease in systolic function but remaining within normal limits **Aortic dimensions** • Aortic root surgery can be considered in those undergoing valve replacement when aortic root >45mm • Marfan syndrome with Ao root >45 mm (or \geq 40 mm in women with low BSA) Bicuspid valve with Ao root >50 mm Tricuspid valve with Ao root >55 mm *Cardiology referral is **not** indicated when valve intervention is highly unlikely to alter prognosis or quality of life (eg, terminal illness, significant frailty)

2021 ESC / EACTS Guidelines for the management of valvular heart disease. European Heart Journal 43(7) 14 and 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. 2024 EACTS/STS Guidelines for diagnosing and treating acute and chronic syndromes of the aortic organ. European Journal of Cardio-Thoracic Surgery 2024, 65(2), ezad426

British Heart Valve Society r Education and Best Practice in Heart Valve Dis





Primary Care Cardiovascular Societu Empowering primary care to deliver the best in cardiovascular health

How this documents works

- 1. Native valve disease:
- Recommendations for the follow up for isolated stenosis or regurgitation • Echo alerts: highlighting echocardiographic features at the time of the scan that should prompt cardiology review in the context of severe valve disease
- Other alerts: Clinical features which should prompt cardiology review in the context of severe valve disease 2. Prosthetic valve follow up:
- Recommendations for the follow up of biological and mechanical valves • Recommendations for aorta follow up post aortic root replacement and post bicuspid aortic valve surgery
- Alerts for repeat echocardiogram and clinical discussion

MITRAL STENOSIS

Severe MS: GP advice: cardiology referral (see red-flags for urgent referral criteria) Echo surveillance interval if asymptomatic: 6 - 12 months*	
Moderate MS: GP advice: routine cardiology referral indicated Echo surveillance interval if asymptomatic: 12 - 24 months*	
Mild MS: GP advice: routine cardiology referral indicated if MS is secondary to rheumatic/ post- inflammatory process / radiotherapy / parachute MV / congenital abnormality Echo surveillance interval: 3 - 5 years or sooner if symptoms develop*	
RED FLAGS REQUIRING URGENT CARDIOLOGY REVIEW: Symptoms Consider advanced imaging if symptoms associated with moderate valve disease Right heart • SPAP >50mmHg • RV impairment or dilatation	
 Heart rhythm New onset atrial fibrillation Stroke risk Confirmed TIA or stroke Dense spontaneous echo contrast seen within the LA 	
*Cardiology referral is <u>not</u> indicated when value intervention is highly unlikely to alter prognosis or quality of life (eg, terminal illness, significant frailty)	

MITRAL REGURGITATION

Severe MR:

GP advice: cardiology referral (see red-flags for urgent referral criteria) Echo surveillance interval if asymptomatic: 6 months

Moderate MR:

GP advice: routine cardiology referral indicated Echo surveillance interval if asymptomatic: 12 - 24 months*

Mild MR:

GP advice: routine cardiology referral indicated if valve structurally abnormal Echo surveillance interval: 3 - 5 years* only if valve is anatomically abnormal, e.g. leaflet prolapse, rheumatic valve disease or other post-inflammatory appearance (previous endocarditis, connective-tissue disorder, autoimmune disorder, carcinoid, drug-induced, radiotherapy induced)

RED FLAGS REQUIRING URGENT CARDIOLOGY REVIEW:
Symptoms
Consider advanced imaging if symptoms associated with moderate valve disease
Left ventricular size and systolic function
LV dilatation
• LVEF <60%
Right heart
SPAP >50mmHg
Heart rhythm
New onset atrial fibrillation
*Cardiology referral is <u>not</u> indicated when valve intervention is highly unlikely to alter prognosis or quality of life (e.g. terminal illness, significant frailty)



Clinical indications and triage of echocardiography

Heart valve disease

Stress testing

Exercise stress echocardiography can be useful in the management of patients with valve disease. We recommend an individualised approach depending on local expertise and infrastructure. **Complex scan follow up**

A number of patients will have more complex disease e.g. \geq moderate multi valve disease; post operative regurgitation with ventricular dysfunction; post operative paravalvular regurgitation etc. For these patients an individualised approach is essential and discussion amongst the clinical team to advise on the surveillance scan period is recommended. Pregnancy

Recommend specialist advice for those with valvular heart disease and / or aortopathy Severe valve disease Moderate valve disease Mild valve disease

HEART VALVE DISEASE

TRICUSPID REGURGITATION

Severe PS: evere TR: **GP** advice: cardiology referral (see red-flags for urgent referral criteria) **P advice:** cardiology referral (see red-flags for urgent referral criteria) Echo surveillance interval if asymptomatic: 12 months cho surveillance interval if asymptomatic: 6 - 12 months* Moderate PS: **Ioderate TR: GP advice:** typically congenitally abnormal valve - cardiology referral indicated **P advice:** cardiology review indicated if any of the below are present: Echo surveillance interval if asymptomatic: 12 - 24 months* Tricuspid valve anatomically abnormal Mild PS: RV impairment and/or dilatation **GP advice:** typically congenitally abnormal valve - cardiology referral indicated Severe RA dilatation Echo surveillance interval: 3 - 5 years* TR caused by RV pacing lead **cho surveillance interval: 12** - 24 months* **RED FLAGS REQUIRING URGENT CARDIOLOGY REVIEW:** Symptoms lild TR: **Right heart P** advice: cardiology referral indicated if either of the below are present: RV impairment Elevated SPAP RV dilatation Tricuspid valve anatomically abnormal *Cardiology referral is **not** indicated when valve intervention is highly unlikely to alter RV impairment and/or dilatation prognosis or quality of life (eg, terminal illness, significant frailty) cho surveillance interval: 3 - 5 years* (if TV abnormal or RV impairment +/- dilatation) ormal valve anatomy and RV size and function - no routine follow-up required **REPAIRED AND REPLACED VALVES** ED FLAGS REQUIRING URGENT CARDIOLOGY REVIEW: Baseline echo: 6 - 8 weeks post op mptoms Mechanical Surveillance: ght heart **RV** dilatation **RV** impairment Baseline echo: 6 -8 weeks post op Surveillance: **Elevated SPAP Biological** Cardiology referral is **not** indicated when valve intervention is highly unlikely to alter (surgical) post implant ognosis or quality of life (e.g. terminal illness, significant frailty) • For new valves with no durability data - annual from implantation 10 years post implant unless alerts Surveillance: Annual if valve parameters are stable TAVI **PULMONARY REGURGITATION** at stage where further intervention unlikely) Severe PR: individualised approach **GP** advice: cardiology referral (see red-flags for urgent referral criteria) Baseline echo: 6 - 8 weeks post op Echo surveillance interval if asymptomatic: 12 months* **Surgical mitral** Surveillance: valve repair • One-year post op • Residual MR mild or less - repeat echo 2 - 3 yearly Moderate PR: **Baseline echo:** 6 - 8 weeks post procedure **GP** advice: Surveillance and cardiology referral are indicated if any one of the below are Surveillance: present Transcathe Residual MR mild or less – annual echo Anatomically abnormal pulmonary valve nitral repa RV impairment and/or dilatation surveillance Pulmonary artery dilatation **Baseline echo:** According to implanted valve History of previous valvuloplasty Aorta Surveillance: Echo surveillance interval if asymptomatic: 12 - 24 months* surveillance following of dilatation progression should be considered bicuspid AV Mild PR: surgery **GP** advice: mild PR is extremely common and usually a normal finding. Surveillance and cardiology referral are only indicated if: Baseline echo: 6 - 8 weeks post op AVR and ro • Anatomically abnormal pulmonary valve Surveillance: eplaceme According to implanted valve type **RED FLAGS REQUIRING URGENT CARDIOLOGY REVIEW:** criteria and consider TOE Symptoms **Right heart** Alerts or **echo/clinical** • New LV dilatation or systolic function impairment. RV dilatation Aortic root dilatation. Urgent review if: discussion RV impairment • Marfan's ≥45mm Bicuspid aortic valve ≥50mm Elevated SPAP • All other patients ≥55mm • Rapid progression >3mm / year

*Cardiology referral is **not** indicated when valve intervention is highly unlikely to alter prognosis or quality of life (eg, terminal illness, significant frailty)

PULMONARY STENOSIS

Baseline TTE normal & no alerts - no routine surveillance required

- MVR/TVR or AVR in patient <60yrs (unless alerts) annual TTE from 5 years
- AVR with proven longevity in patient >60yrs annual surveillance TTE from

Baseline echo: 6 - 8 weeks post implant or as directed by operator

- Increase surveillance interval to 2 yearly if parameters remain stable (unless
- If other native valve stenosis/regurgitation, review by native valve criteria Complex cases with ventricular dysfunction or multi native valve disease:

- Residual MR greater than mild review by native valve criteria

- Residual MR greater than mild review by native valve criteria/individualised

- Individualised approach by clinical team as cross sectional imaging may be preferred to echo for aorta surveillance. Factors such as aorta size and rate
- If discrepancy >2 mm between TTE and CT/MRI interval imaging with CT

Other

onsideration

- New or worsening prosthetic valve regurgitation: review by native valve
- Gradient or effective orifice area outside of expected parameters.
- Mechanical prosthetic values with INR subtherapeutic for extended period

- Clinical suspicion of endocarditis +/- high risk features.
- If other native valve disease, echo surveillance as per native valve criteria
- Consider discharge from routine echo surveillance if patient would not be considered for re-intervention on account of frailty / co-morbidities
- For bioprosthetic valve dysfunction individualised approach for surveillance frequency